Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults.

CONCLUSIONS: GX-H9 has the potential for up to twice-monthly administration.
PMID: 29973375 [PubMed - as supplied by publisher]

Source: European Journal of Endocrinology - July 4, 2018 Category: Endocrinology Authors: Ku CR, Brue T, Schilbach K, Ignatenko S, Magony S, Chung YS, Kim BJ, Hur KY, Kang HC, Kim JH, Kim MS, Kowalska A, Bolanowski M, Ruchala M, Damjanovic S, Payer J, Choi YJ, Heo SJ, Kim TK, Heo M, Lee J, Lee EJ Tags: Eur J Endocrinol Source Type: research